RXi Pharmaceuticals Corp (NASDAQ:RXII) has received a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that cover the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy rating.
Analysts have set a 1-year consensus price target of $2.00 for the company and are anticipating that the company will post ($0.45) earnings per share for the current quarter, according to Zacks. Zacks has also given RXi Pharmaceuticals an industry rank of 90 out of 255 based on the ratings given to related companies.
RXII has been the topic of several research analyst reports. HC Wainwright initiated coverage on RXi Pharmaceuticals in a report on Monday, July 9th. They issued a “buy” rating and a $3.00 price objective on the stock. ValuEngine upgraded RXi Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, August 2nd.
RXi Pharmaceuticals (NASDAQ:RXII) last announced its quarterly earnings results on Tuesday, August 14th. The biotechnology company reported ($0.46) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.62) by $0.16. The business had revenue of $0.06 million during the quarter, compared to analyst estimates of $0.02 million. On average, research analysts expect that RXi Pharmaceuticals will post -1.55 earnings per share for the current year.
A hedge fund recently bought a new stake in RXi Pharmaceuticals stock. SG Americas Securities LLC acquired a new stake in RXi Pharmaceuticals Corp (NASDAQ:RXII) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 118,387 shares of the biotechnology company’s stock, valued at approximately $228,000. SG Americas Securities LLC owned 2.78% of RXi Pharmaceuticals at the end of the most recent quarter. Institutional investors and hedge funds own 8.87% of the company’s stock.
About RXi Pharmaceuticals
RXi Pharmaceuticals Corporation, a biotechnology company, focuses on discovering and developing immuno-oncology therapeutics to treat cancer. The company's lead product candidate is RXI-109, an sd-rxRNA that reduces the expression of connective tissue growth factor, a critical regulator of several biological pathways involved in fibrosis, including scar formation in the skin and eye.
Further Reading: Beta
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for RXi Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RXi Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.